261 related articles for article (PubMed ID: 28085111)
1. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
[TBL] [Abstract][Full Text] [Related]
3. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.
Li R; Liu GZ; Luo SY; Chen R; Zhang JX
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4533-41. PubMed ID: 26698249
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
[TBL] [Abstract][Full Text] [Related]
5. AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer.
Bi L; Ma F; Tian R; Zhou Y; Lan W; Song Q; Cheng X
Gene; 2018 Feb; 644():148-154. PubMed ID: 29126926
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1.
Mohanty S; Huang J; Basu A
Clin Cancer Res; 2005 Sep; 11(18):6730-7. PubMed ID: 16166454
[TBL] [Abstract][Full Text] [Related]
7. Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/β-catenin signaling pathway in cervical cancer.
Wang T; Liu Z; Shi F; Wang J
Mol Cell Biochem; 2016 Feb; 413(1-2):179-87. PubMed ID: 26820938
[TBL] [Abstract][Full Text] [Related]
8. MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1.
Chen J; Li G
Biomed Pharmacother; 2018 Nov; 107():997-1003. PubMed ID: 30257412
[TBL] [Abstract][Full Text] [Related]
9. SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines.
Chen X; Xiong D; Ye L; Yang H; Mei S; Wu J; Chen S; Mi R
Cancer Chemother Pharmacol; 2019 Apr; 83(4):603-613. PubMed ID: 30627777
[TBL] [Abstract][Full Text] [Related]
10. Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells.
Mehta H; Ambele MA; Mokgautsi N; Moela P
Cells; 2024 Apr; 13(8):. PubMed ID: 38667315
[TBL] [Abstract][Full Text] [Related]
11. miR-205 Promotes Apoptosis of Cervical Cancer Cells and Enhances Drug Sensitivity of Cisplatin by Inhibiting YAP1.
Li X; Li Y; Han Y; Dong B; Liu D; Che L; Liu Y; Wang Y
Cancer Biother Radiopharm; 2020 Jun; 35(5):338-344. PubMed ID: 32379984
[No Abstract] [Full Text] [Related]
12. Protein kinase C β inhibits autophagy and sensitizes cervical cancer Hela cells to cisplatin.
Li N; Zhang W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28246354
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
14. NHERF1 Suppresses Lung Cancer Cell Migration by Regulation of Epithelial-Mesenchymal Transition.
Yang F; Gu Y; Zhao Z; Huang J; Jiang WG; Cheng S
Anticancer Res; 2017 Aug; 37(8):4405-4414. PubMed ID: 28739734
[TBL] [Abstract][Full Text] [Related]
15. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
Myers AL; Lin L; Nancarrow DJ; Wang Z; Ferrer-Torres D; Thomas DG; Orringer MB; Lin J; Reddy RM; Beer DG; Chang AC
Oncotarget; 2015 Sep; 6(28):25897-916. PubMed ID: 26317790
[TBL] [Abstract][Full Text] [Related]
16. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
[TBL] [Abstract][Full Text] [Related]
17. miR‑519d‑3p/HIF‑2α axis increases the chemosensitivity of human cervical cancer cells to cisplatin via inactivation of PI3K/AKT signaling.
Jiang L; Shi S; Li F; Shi Q; Zhong T; Zhang H; Xia Y
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760204
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance.
Leisching G; Loos B; Botha M; Engelbrecht AM
J Transl Med; 2015 Oct; 13():328. PubMed ID: 26474854
[TBL] [Abstract][Full Text] [Related]
19. PSAT1 Upregulation Contributes to Cell Growth and Cisplatin Resistance in Cervical Cancer Cells via Regulating PI3K/AKT Signaling Pathway.
Duan W; Liu X
Ann Clin Lab Sci; 2020 Jul; 50(4):512-518. PubMed ID: 32826249
[TBL] [Abstract][Full Text] [Related]
20. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
Kong LR; Chua KN; Sim WJ; Ng HC; Bi C; Ho J; Nga ME; Pang YH; Ong WR; Soo RA; Huynh H; Chng WJ; Thiery JP; Goh BC
Mol Cancer Ther; 2015 Jul; 14(7):1750-60. PubMed ID: 25939760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
